1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Canada >
  5. Quebec >
  6. Emerillon Therapeutics Acquires Hemax Genome

M&A Deal Summary

Emerillon Therapeutics Acquires Hemax Genome

On October 7, 2005, Emerillon Therapeutics acquired life science company Hemax Genome

Acquisition Highlights
  • This is Emerillon Therapeutics’ 1st transaction in the Life Science sector.
  • This is Emerillon Therapeutics’ 1st transaction in Canada.
  • This is Emerillon Therapeutics’ 1st transaction in Quebec.

M&A Deal Summary
Date 2005-10-07
Target Hemax Genome
Sector Life Science
Buyer(s) Emerillon Therapeutics
Deal Type Add-on Acquisition

Target

Hemax Genome

Montreal, Quebec, Canada
Hemax Genome, Inc. is a biotechnology company identifies genes of medical interest localized on chromosome X.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Emerillon Therapeutics

Montréal, Quebec, Canada
Category Company
Sector Life Science
DESCRIPTION

Emerillon Therapeutics, Inc. is a biotechnology company discovers and develops genomics-based drugs for infectious diseases.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Quebec M&A 1 of 1
Country: Canada M&A 1 of 1
Year: 2005 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal